SG10201913685YA - Fibronectin based scaffold domain proteins that bind to myostatin - Google Patents

Fibronectin based scaffold domain proteins that bind to myostatin

Info

Publication number
SG10201913685YA
SG10201913685YA SG10201913685YA SG10201913685YA SG10201913685YA SG 10201913685Y A SG10201913685Y A SG 10201913685YA SG 10201913685Y A SG10201913685Y A SG 10201913685YA SG 10201913685Y A SG10201913685Y A SG 10201913685YA SG 10201913685Y A SG10201913685Y A SG 10201913685YA
Authority
SG
Singapore
Prior art keywords
myostatin
bind
domain proteins
based scaffold
scaffold domain
Prior art date
Application number
SG10201913685YA
Other languages
English (en)
Inventor
Sharon Cload
Linda Engle
Dasa Lipovsek
Malavi Madireddi
Ginger RAKESTRAW
Joanna Swain
Wenjun Zhao
Hui Wei
Aaron Yamniuk
Vidhyashankar Ramamurthy
Alexander Kozhich
Martin Corbett
Stanley Krystek
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49253416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201913685Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SG10201913685YA publication Critical patent/SG10201913685YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
SG10201913685YA 2012-09-13 2013-09-12 Fibronectin based scaffold domain proteins that bind to myostatin SG10201913685YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261700697P 2012-09-13 2012-09-13
US201361780005P 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
SG10201913685YA true SG10201913685YA (en) 2020-03-30

Family

ID=49253416

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201701970TA SG10201701970TA (en) 2012-09-13 2013-09-12 Fibronectin based scaffold domain proteins that bind to myostatin
SG11201501741YA SG11201501741YA (en) 2012-09-13 2013-09-12 Fibronectin based scaffold domain proteins that bind to myostatin
SG10201913685YA SG10201913685YA (en) 2012-09-13 2013-09-12 Fibronectin based scaffold domain proteins that bind to myostatin

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG10201701970TA SG10201701970TA (en) 2012-09-13 2013-09-12 Fibronectin based scaffold domain proteins that bind to myostatin
SG11201501741YA SG11201501741YA (en) 2012-09-13 2013-09-12 Fibronectin based scaffold domain proteins that bind to myostatin

Country Status (32)

Country Link
US (8) US8933199B2 (fr)
EP (3) EP2895503B1 (fr)
JP (2) JP6346895B2 (fr)
KR (3) KR102424590B1 (fr)
CN (2) CN104768969B (fr)
AU (2) AU2013315482B2 (fr)
BR (1) BR112015005466B1 (fr)
CA (1) CA2884730C (fr)
CL (1) CL2015000500A1 (fr)
DK (2) DK3564258T3 (fr)
EA (1) EA033536B1 (fr)
ES (2) ES2727453T3 (fr)
HK (1) HK1212717A1 (fr)
HR (2) HRP20190845T1 (fr)
HU (2) HUE043482T2 (fr)
IL (3) IL270110B (fr)
LT (3) LT3835310T (fr)
MX (2) MX366666B (fr)
MY (2) MY172863A (fr)
NZ (1) NZ628446A (fr)
PE (1) PE20150954A1 (fr)
PH (1) PH12015500397A1 (fr)
PL (2) PL2895503T3 (fr)
PT (2) PT2895503T (fr)
RS (2) RS58801B1 (fr)
SG (3) SG10201701970TA (fr)
SI (2) SI3564258T1 (fr)
TN (1) TN2015000086A1 (fr)
TW (2) TWI694085B (fr)
UY (1) UY35027A (fr)
WO (1) WO2014043344A1 (fr)
ZA (1) ZA201501457B (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2568436T3 (es) 2006-03-31 2016-04-29 Chugai Seiyaku Kabushiki Kaisha Procedimiento para controlar la farmacocinética en sangre de anticuerpos
EP3689912A1 (fr) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Procédé de modification d'un anticorps par point isoélectrique par substitution d'acide aminé dans cdr
EP4238993A3 (fr) 2008-04-11 2023-11-29 Chugai Seiyaku Kabushiki Kaisha Molécule de liaison à l'antigène capable de se lier à deux ou plusieurs molécules d'antigène de manière répétée
US9562089B2 (en) * 2010-05-26 2017-02-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
SG190727A1 (en) 2010-11-30 2013-07-31 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
PT2697257T (pt) * 2011-04-13 2016-12-28 Bristol Myers Squibb Co Proteínas de fusão fc compreendendo novos ligantes ou arranjos
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
TWI697501B (zh) 2012-08-24 2020-07-01 日商中外製藥股份有限公司 ＦｃγＲＩＩｂ特異性Ｆｃ區域變異體
CN104768969B (zh) 2012-09-13 2021-04-16 百时美施贵宝公司 结合至肌生成抑制素的基于纤连蛋白的支架结构域蛋白
ES2715710T3 (es) 2013-01-25 2019-06-05 Shire Human Genetic Therapies Folistatina en el tratamiento de la distrofía muscular de Duchenne
US20150361159A1 (en) 2013-02-01 2015-12-17 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
EP3406629B1 (fr) 2013-02-06 2020-06-24 Bristol-Myers Squibb Company Protéines du domaine de la fibronectine de type iii à solubilité améliorée
US10065987B2 (en) 2013-02-12 2018-09-04 Bristol-Myers Squibb Company High pH protein refolding methods
WO2014163101A1 (fr) 2013-04-02 2014-10-09 中外製薬株式会社 Variant de région fc
EP3816625A1 (fr) 2013-05-06 2021-05-05 Scholar Rock, Inc. Compositions et procédés de modulation de facteur de croissance
MX2016011580A (es) 2014-03-20 2016-11-29 Bristol Myers Squibb Co Dominios de fibronectina tipo iii que se unen a albumina de suero.
EP3647322B1 (fr) 2014-03-20 2021-10-20 Bristol-Myers Squibb Company Molécules de charpente à base de fibronectine stabilisée
US10016394B2 (en) 2014-04-16 2018-07-10 The Scripps Research Institute PPARG modulators for treatment of osteoporosis
US11072681B2 (en) 2014-07-28 2021-07-27 The Regents Of The University Of California Compositions and methods of making polymerizing nucleic acids
WO2016023036A1 (fr) * 2014-08-08 2016-02-11 The Regents Of The University Of California Polymères peptidiques à haute densité
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
EP3789399A1 (fr) 2014-11-21 2021-03-10 Bristol-Myers Squibb Company Anticorps comprenant des régions constantes de chaîne lourde modifiées
KR102569813B1 (ko) 2014-11-21 2023-08-24 브리스톨-마이어스 스큅 컴퍼니 Cd73에 대항한 항체 및 그의 용도
CN107207379B (zh) 2014-11-25 2021-08-10 百时美施贵宝公司 用于生物制品的18f-放射性标记的方法和组合物
ES2822990T3 (es) 2014-11-25 2021-05-05 Bristol Myers Squibb Co Novedosos polipéptidos de unión a PD-L1 para obtención de imágenes
TWI808330B (zh) 2014-12-19 2023-07-11 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法
MA40662B1 (fr) 2014-12-23 2020-12-31 Bristol Myers Squibb Co Anticorps contre tigit
TW202248212A (zh) 2015-02-05 2022-12-16 日商中外製藥股份有限公司 包含離子濃度依賴之抗原結合域的抗體、Fc區變體、IL-8結合抗體與其用途
US10993993B2 (en) * 2015-05-28 2021-05-04 Immunoforge Co., Ltd. Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist
MY188049A (en) 2015-05-29 2021-11-12 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof
EA201890162A1 (ru) 2015-06-29 2018-07-31 Бристол-Маерс Сквибб Компани Антитела к cd40 с повышенной агонистической активностью
WO2017040332A1 (fr) * 2015-08-28 2017-03-09 University Of Massachusetts Quantification du transport axonal net dans des pathologies motoneuronales
CN108350416A (zh) 2015-11-09 2018-07-31 百时美施贵宝公司 操纵在cho细胞中产生的多肽的品质属性的方法
EP3394098A4 (fr) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-myostatine et procédés d'utilisation
EP3423489A1 (fr) 2016-03-04 2019-01-09 The Rockefeller University Anticorps anti-cd40 présentant une activité agoniste renforcée
SG10201913033UA (en) 2016-03-04 2020-03-30 Bristol Myers Squibb Co Combination therapy with anti-cd73 antibodies
RU2613420C1 (ru) * 2016-04-13 2017-03-16 Сергей Михайлович Юдин Рекомбинантный белок Мио-ГСД, способ его получения, инъекционный препарат для повышения мышечной массы сельскохозяйственных животных, птицы и животных семейства псовых, а также способ использования препарата
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
ES2874974T3 (es) 2016-05-11 2021-11-05 Cytiva Bioprocess R & D Ab Matriz de separación
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
JP7106187B2 (ja) 2016-05-11 2022-07-26 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックスを保存する方法
CN109311948B (zh) 2016-05-11 2022-09-16 思拓凡生物工艺研发有限公司 清洁和/或消毒分离基质的方法
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
CN109562195A (zh) 2016-06-01 2019-04-02 百时美施贵宝公司 用pd-l1结合多肽进行pet成像
CN109789197A (zh) * 2016-08-03 2019-05-21 奈斯科尔公司 用于调节lair信号转导的组合物和方法
EP3494991A4 (fr) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Composition pour la prophylaxie ou le traitement de maladies liées à il-8
EP3549595A4 (fr) * 2016-12-05 2020-07-22 Otsuka Pharmaceutical Co., Ltd. Composition inhibant l'amyotrophie
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
TW201842929A (zh) 2017-05-03 2018-12-16 美商必治妥美雅史谷比公司 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物
CA3064321A1 (fr) 2017-05-25 2018-11-29 Bristol-Myers Squibb Company Anticorps comprenant des regions constantes de chaine lourde modifiees
WO2019133747A1 (fr) 2017-12-27 2019-07-04 Bristol-Myers Squibb Company Anticorps anti-cd40 et leurs utilisations
JP7102670B2 (ja) * 2018-01-25 2022-07-20 アイ－エムエービー バイオファーマ ユーエス リミテッド 抗ｐｄ‐ｌ１抗体とｉｌ‐７との融合
CN108593615A (zh) * 2018-05-02 2018-09-28 浠思（上海）生物技术有限公司 利用htrf一步法筛选pd1/pd-l1阻断剂的方法
JP7051656B2 (ja) 2018-09-28 2022-04-11 三菱重工コンプレッサ株式会社 タービンステータ、蒸気タービン、及び仕切板
AU2019380307A1 (en) 2018-11-16 2021-07-01 Bristol-Myers Squibb Company Anti-NKG2A antibodies and uses thereof
EP3887397A1 (fr) 2018-11-28 2021-10-06 Bristol-Myers Squibb Company Anticorps comprenant des régions constantes de chaîne lourde modifiées
JP2023516459A (ja) 2020-03-09 2023-04-19 ブリストル－マイヤーズ スクイブ カンパニー 増強されたアゴニスト活性を有するｃｄ４０に対する抗体
WO2021231732A1 (fr) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Anticorps anti-garp
US11566346B2 (en) * 2020-06-25 2023-01-31 Philip David Rodley Protein scaffold
WO2023196818A1 (fr) 2022-04-04 2023-10-12 The Regents Of The University Of California Compositions et procédés de complémentation génétique

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5641648A (en) 1986-11-04 1997-06-24 Protein Polymer Technologies, Inc. Methods for preparing synthetic repetitive DNA
US5514581A (en) 1986-11-04 1996-05-07 Protein Polymer Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
US5770697A (en) 1986-11-04 1998-06-23 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US5589173A (en) 1986-11-04 1996-12-31 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
US6018030A (en) 1986-11-04 2000-01-25 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5792742A (en) 1991-06-14 1998-08-11 New York University Fibrin-binding peptide fragments of fibronectin
EP0752248B1 (fr) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Application thérapeutique d'anticorps chimériques et radio-marqués contre l'antigène à differentiation restreinte des lymphocytes B humains pour le traitement du lymphome des cellules B
WO1994017097A1 (fr) 1993-01-19 1994-08-04 Regents Of The University Of Minnesota Fragments de fibronectine synthetique utilises comme inhibiteurs d'infections retrovirales
US6465239B1 (en) 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
EP1333035A3 (fr) 1993-03-19 2004-07-07 The Johns Hopkins University School Of Medicine Facteur GDF-8 de différentiation de croissance
US6607884B1 (en) 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US20030074680A1 (en) 1993-03-19 2003-04-17 Johns Hopkins University School Of Medicine Growth differentiation factor-8
US6673534B1 (en) 1995-10-26 2004-01-06 The Johns Hopkins University School Of Medicine Methods for detection of mutations in myostatin variants
US7332575B2 (en) 1994-03-18 2008-02-19 The Johns Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
ATE332368T1 (de) 1997-01-21 2006-07-15 Gen Hospital Corp Selektion von proteinen mittels rns-protein fusionen
AU6274298A (en) 1997-02-05 1998-08-25 Johns Hopkins University School Of Medicine, The Growth differentiation factor-8
US7749498B2 (en) 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
EP0985039B1 (fr) 1997-06-12 2008-02-20 Novartis International Pharmaceutical Ltd. Polypeptides d'anticorps artificiels
CA2323638A1 (fr) 1998-04-03 1999-10-14 Phylos, Inc. Systemes de proteines adressables
EP1075272B1 (fr) 1998-05-06 2009-07-15 Metamorphix, Inc. Methodes de traitement du diabete par inhibition du gdf-8
EP2154535A1 (fr) 1998-12-10 2010-02-17 Bristol-Myers Squibb Company Supports de protéine pour mimer des anticorps et d'autres protéines de liaison
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) * 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
EP1268544A2 (fr) 2000-03-31 2003-01-02 Institut Pasteur Peptides inhibant l'angiogenese induite par le vegf (facteur de croissance endotheliale), polynucleotides codant pour ces peptides et leurs procedes d'utilisation
ES2564161T3 (es) 2000-07-11 2016-03-18 Research Corporation Technologies, Inc Polipéptidos de anticuerpos artificiales
JP2004526419A (ja) 2000-10-16 2004-09-02 フィロス インク． 抗体模倣物および他の結合タンパク質のためのタンパク質骨格
US7598352B2 (en) 2000-11-17 2009-10-06 University Of Rochester Method of identifying polypeptide monobodies which bind to target proteins and use thereof
CA2442092A1 (fr) 2001-03-26 2002-10-17 Ribozyme Pharmaceuticals, Inc. Inhibition regulee par des oligonucleotides de la replication du virus de l'hepatite b et du virus de l'hepatite c
US7556925B2 (en) 2001-04-04 2009-07-07 University Of Rochester ανβ3 integrin-binding polypeptide monobodies and their use
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
WO2003104418A2 (fr) 2002-06-06 2003-12-18 Research Corporation Technologies, Inc. Polypeptides reconstitues
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
ES2655912T3 (es) 2002-11-08 2018-02-22 Ablynx N.V. Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos
AU2004296376B2 (en) 2003-12-05 2010-03-04 Bristol-Myers Squibb Company Inhibitors of type 2 vascular endothelial growth factor receptors
US20080220049A1 (en) 2003-12-05 2008-09-11 Adnexus, A Bristol-Myers Squibb R&D Company Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
MXPA06009072A (es) 2004-02-09 2007-03-29 Human Genome Sciences Inc Proteinas de fusion de albumina.
WO2005094446A2 (fr) 2004-03-23 2005-10-13 Eli Lilly And Company Anticorps diriges contre la myostatine
WO2005118646A2 (fr) 2004-04-26 2005-12-15 Centocor, Inc. Selection dirigee vers des epitopes, d'anticorps antifacteur de tissu murin
KR20070083941A (ko) 2004-10-04 2007-08-24 큐엘티 유에스에이, 인코포레이티드 중합체 전달 조성을 갖는 눈 전달
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
MX2007013217A (es) 2005-04-25 2008-03-11 Pfizer Anticuerpos contra miostatina.
CN103450359B (zh) 2005-08-19 2018-07-24 惠氏有限责任公司 抗gdf-8的拮抗剂抗体以及在als和其他gdf-8-相关病症治疗中的用途
EP1951756B1 (fr) 2005-10-06 2015-01-07 Eli Lilly And Company Anticorps anti-myostatine
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
EP1968621A2 (fr) 2005-12-06 2008-09-17 Amgen Inc. Utilisations d'antagonistes de la myostatine
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
PT2066695E (pt) 2006-09-05 2013-05-23 Lilly Co Eli Anticorpos anti-miostatina
WO2008031098A1 (fr) 2006-09-09 2008-03-13 The University Of Chicago Bibliothèques d'acides aminés binaires pour monocorps polypeptidiques de fibronectines de type iii
BRPI0719597A2 (pt) 2006-11-22 2013-12-17 Adnexus A Bristol Myers Squibb R & D Company Produtos terapêuticos objetivados baseados em proteínas manipuladas para receptores de quinases de tirosina, incluindo igf-ir
US20100144599A1 (en) 2007-02-02 2010-06-10 Bristol-Myers Squibb Company Vegf pathway blockade
AU2008262490B2 (en) 2007-05-22 2011-11-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
US8680019B2 (en) 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
AU2008287426B2 (en) 2007-08-10 2014-06-26 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
WO2009025806A2 (fr) 2007-08-20 2009-02-26 Adnexus, A Bristol-Myers Squibb R & D Company Compositions et procédés de traitement d'un cancer métastatique
KR100857861B1 (ko) * 2007-10-15 2008-09-11 주식회사 바이오리더스 Ｍｙｏ－２ 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물
CA2704229C (fr) 2007-10-31 2019-05-07 Medimmune, Llc Structures proteiques
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US20110034384A1 (en) 2007-11-28 2011-02-10 Bristol-Myers Squibb Company COMBINATION VEGFR2 THERAPY WITH mTOR INHIBITORS
JP2011507529A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド Ｍ１３ファージのｐＩＸへの融合を介する代替の足場タンパク質融合ファージ提示
US20100322930A1 (en) 2007-12-27 2010-12-23 Frank Kolbinger Fibronectin-based binding molecules and their use
EP2080812A1 (fr) 2008-01-18 2009-07-22 Transmedi SA Compositions et procédés pour détecter des peptides post-stop
WO2009102421A2 (fr) 2008-02-14 2009-08-20 Bristol-Myers Squibb Company Agents thérapeutiques cibles basés sur des protéines fabriquées qui se lient au récepteur de l’egf
WO2009133208A1 (fr) 2008-05-02 2009-11-05 Novartis Ag Molécules de liaison à base de fibronectine améliorées et leurs utilisations
JP2011520961A (ja) 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー 多価フィブロネクチンをベースとする足場ドメインタンパク質
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
PL2356269T3 (pl) 2008-10-31 2016-12-30 Kompozycje białek rusztowania oparte na domenie fibronektyny typu III, sposoby i zastosowania
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
WO2010069913A1 (fr) 2008-12-16 2010-06-24 Novartis Ag Systèmes de présentation de levures
AR074777A1 (es) * 2008-12-19 2011-02-09 Glaxo Group Ltd Proteinas de union a antigeno
WO2010093771A1 (fr) 2009-02-11 2010-08-19 Bristol-Myers Squibb Company Thérapie vegfr2 de combinaison avec le témozolomide
CN102596992B (zh) 2009-02-12 2015-09-09 詹森生物科技公司 基于ⅲ型纤连蛋白结构域的支架组合物、方法及用途
US8067201B2 (en) 2009-04-17 2011-11-29 Bristol-Myers Squibb Company Methods for protein refolding
EP2464663A4 (fr) 2009-08-13 2013-05-29 Massachusetts Inst Technology Protéines recombinées comprenant des domaines mutants de fibronectine
ES2860453T3 (es) 2009-10-30 2021-10-05 Novartis Ag Bibliotecas universales del dominio de unión del lado inferior de la fibronectina de tipo III
WO2011051466A1 (fr) 2009-11-02 2011-05-05 Novartis Ag Molécules de liaison anti-idiotypiques à base de fibronectine et leurs utilisations
US20110123545A1 (en) 2009-11-24 2011-05-26 Bristol-Myers Squibb Company Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases
WO2011092233A1 (fr) 2010-01-29 2011-08-04 Novartis Ag Conjugaison de levures pour produire des combinaisons de liants à base de fibronectine à haute affinité
US8961977B2 (en) 2010-02-12 2015-02-24 University Of Rochester Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
BR112012019881A2 (pt) 2010-02-18 2017-06-27 Bristol Myers Squibb Co proteínas de domínio estrutural baseadas na fibronectina que ligam-se à il-23
DK2558491T3 (en) * 2010-04-13 2018-10-15 Bristol Myers Squibb Co Fibronectin-based Scaffold domain proteins that bind PCSK9
WO2011130324A1 (fr) 2010-04-13 2011-10-20 Medimmune, Llc Échafaudages multimériques à base de domaine de fibronectine de type iii
EP3569256B1 (fr) 2010-04-30 2022-06-15 Janssen Biotech, Inc. Compositions de domaine de fibronectine stabilisées, procédés et utilisations
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
US9562089B2 (en) 2010-05-26 2017-02-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
EP3248987A1 (fr) 2010-07-30 2017-11-29 Novartis AG Molécules de berceau de fibronectine et leurs banques
EP2606066A1 (fr) 2010-08-16 2013-06-26 Amgen Inc. Anticorps se liant à la myostatine, compositions et procédés
US9260496B2 (en) * 2010-12-22 2016-02-16 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind IL-23
PT2697257T (pt) 2011-04-13 2016-12-28 Bristol Myers Squibb Co Proteínas de fusão fc compreendendo novos ligantes ou arranjos
EP2709669A1 (fr) 2011-05-17 2014-03-26 Bristol-Myers Squibb Company Procédés de maintien de la pegylation de polypeptides
EP3318880B1 (fr) 2011-05-17 2020-12-16 Bristol-Myers Squibb Company Procédés améliorés pour la sélection de protéines de liaison
EP3540100B8 (fr) 2011-09-27 2022-11-02 Janssen Biotech, Inc. Échafaudage de protéine à base de répétition de fibronectine de type iii avec des surfaces de liaison alternatives
JP2015525230A (ja) 2012-06-11 2015-09-03 アムジエン・インコーポレーテツド デュアル受容体アンタゴニスト性抗原結合タンパク質およびその使用
EP2861617A1 (fr) 2012-06-15 2015-04-22 Pfizer Inc. Anticorps antagonistes améliorés dirigés contre gdf-8 et leurs utilisations
CN104768969B (zh) 2012-09-13 2021-04-16 百时美施贵宝公司 结合至肌生成抑制素的基于纤连蛋白的支架结构域蛋白
TW201842929A (zh) 2017-05-03 2018-12-16 美商必治妥美雅史谷比公司 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物

Also Published As

Publication number Publication date
US20170354718A1 (en) 2017-12-14
TWI633117B (zh) 2018-08-21
MX2015002894A (es) 2015-06-03
PT3564258T (pt) 2021-06-30
EP3564258A1 (fr) 2019-11-06
LT3564258T (lt) 2021-08-25
ES2727453T3 (es) 2019-10-16
NZ628446A (en) 2017-06-30
PT2895503T (pt) 2019-06-03
US20190307855A1 (en) 2019-10-10
DK2895503T3 (da) 2019-05-27
TW201823269A (zh) 2018-07-01
KR102187714B1 (ko) 2020-12-07
EP3564258B1 (fr) 2021-04-28
US20170088602A1 (en) 2017-03-30
CN104768969B (zh) 2021-04-16
KR102424590B1 (ko) 2022-07-27
JP6346895B2 (ja) 2018-06-20
JP2015530390A (ja) 2015-10-15
US20140309163A1 (en) 2014-10-16
IL237559A0 (en) 2015-04-30
TWI694085B (zh) 2020-05-21
AU2018201273B2 (en) 2020-04-09
US20150072919A1 (en) 2015-03-12
US10406212B2 (en) 2019-09-10
TW201416376A (zh) 2014-05-01
AU2013315482A1 (en) 2015-03-12
KR20220107082A (ko) 2022-08-01
PE20150954A1 (es) 2015-06-20
WO2014043344A1 (fr) 2014-03-20
IL270110A (fr) 2019-12-31
EP2895503A1 (fr) 2015-07-22
CN108409856B (zh) 2022-03-04
DK3564258T3 (da) 2021-06-21
CN104768969A (zh) 2015-07-08
US20140107020A1 (en) 2014-04-17
LT3835310T (lt) 2024-04-25
HK1212717A1 (zh) 2016-06-17
PH12015500397B1 (en) 2015-04-27
HRP20210990T1 (hr) 2021-09-17
EA033536B1 (ru) 2019-10-31
SG10201701970TA (en) 2017-05-30
SI3564258T1 (sl) 2021-07-30
CA2884730C (fr) 2023-07-04
IL294314A (en) 2022-08-01
AU2013315482B2 (en) 2018-03-15
KR20150054938A (ko) 2015-05-20
MX2019008391A (es) 2019-09-09
ZA201501457B (en) 2021-09-29
SG11201501741YA (en) 2015-04-29
EP3835310B1 (fr) 2024-03-20
EP2895503B1 (fr) 2019-03-27
CN108409856A (zh) 2018-08-17
IL237559B (en) 2019-10-31
RS62009B1 (sr) 2021-07-30
PH12015500397A1 (en) 2015-04-27
TN2015000086A1 (en) 2016-06-29
MY172863A (en) 2019-12-13
HRP20190845T1 (hr) 2019-08-09
CA2884730A1 (fr) 2014-03-20
US8933199B2 (en) 2015-01-13
UY35027A (es) 2014-03-31
RS58801B1 (sr) 2019-07-31
LT2895503T (lt) 2019-07-25
KR20200138435A (ko) 2020-12-09
HUE054699T2 (hu) 2021-09-28
US8853154B2 (en) 2014-10-07
IL270110B (en) 2022-08-01
JP6793680B2 (ja) 2020-12-02
US10245302B2 (en) 2019-04-02
MX366666B (es) 2019-07-19
AU2018201273A1 (en) 2018-03-15
BR112015005466B1 (pt) 2023-04-11
MY189682A (en) 2022-02-25
JP2018183138A (ja) 2018-11-22
EA201590543A1 (ru) 2015-06-30
US8993265B2 (en) 2015-03-31
US9662373B2 (en) 2017-05-30
US9493546B2 (en) 2016-11-15
BR112015005466A2 (pt) 2017-08-08
EP3835310A1 (fr) 2021-06-16
SI2895503T1 (sl) 2019-08-30
HUE043482T2 (hu) 2019-08-28
US11813315B2 (en) 2023-11-14
US20140105896A1 (en) 2014-04-17
PL3564258T3 (pl) 2021-10-25
PL2895503T3 (pl) 2019-09-30
US20150231211A1 (en) 2015-08-20
ES2879387T3 (es) 2021-11-22
CL2015000500A1 (es) 2015-07-31

Similar Documents

Publication Publication Date Title
HK1212717A1 (zh) 結合至肌生成抑制素的基於纖連蛋白的支架結構域蛋白
HK1257028A1 (zh) 可注射製劑
ZA201408580B (en) Detergent composition
HK1179276A1 (en) Fibronectin based scaffold domain proteins that bind il-23 il-23
ZA201500575B (en) Adw detergent composition
PL2662436T3 (pl) Kompozycja detergentu
SG11201504939RA (en) Microcontroller
BR302013002335S1 (pt) Configuração aplicada em porta-objetos
EP2861068A4 (fr) Méthodes associées au bevacizumab
HK1204551A1 (en) Injectable compositions
EP2856158A4 (fr) Méthodes associées au rituximab
BR112015012440A2 (pt) composição de limpeza
GB2507762B (en) Improvements to dartboards
ZA201504070B (en) Detergent composition
GB201215288D0 (en) Improvements relating to firelighters
GB201206287D0 (en) Bid to rent property
BR302012004065S1 (pt) Configuração aplicada me recipiente anatômico
BR302012002575S1 (pt) Configuração aplicada em caneca barril
GB201201142D0 (en) Sdd